government backed cryptocurrency, Top stories

Qianyuan Medicine established a research and development company in Shanghai. According to the enterprise search APP, Qianyuan Medicine Research and Development (Shanghai) Co., Ltd. was recently established, with Mao Rengang as the legal representative and a registered capital of 10 million yuan. Its business scope includes: medical research and experimental development; Technical service, technical development, technical consultation, technical exchange, technology transfer and technology popularization. Enterprise investigation shows that the company is wholly owned by Qianyuan Medicine.TikTok submitted an application to the federal court of Canada to challenge the Canadian government's order to close the company's office. On December 11th, local time, TikTok Canada Branch announced that it had submitted an application to the federal court for review of the government's order to close TikTok's business in Canada. TikTok said that this order will cost hundreds of hard-working local employees their jobs and livelihoods, and they support the community with more than 14 million Canadian users on TikTok every month. TikTok said that it is in the best interest of Canadians to find a meaningful solution and ensure that the local team continues to exist with the TikTok platform. (Interface News)The Hang Seng Science and Technology Index rose to 1%, and the Hang Seng Index is now up 0.70%.

The first demonstration in China! Seiko Technology's high-performance PAN fiber technology has made key progress, and Seiko Technology's high-performance fiber precursor (polymerization process) "The first demonstration of safety and reliability of chemical process used in China" has successfully passed the evaluation of the expert group, which indicates that Seiko Technology's carbon fiber precursor preparation technology can be applied to industrialization on a large scale. On December 7th, Zhejiang Petroleum and Chemical Industry Association, entrusted by Zhejiang Emergency Management Department, organized and held the review meeting of "Demonstration of Safety and Reliability of Chemical Process Used for the First time in China" for high-performance PAN fiber in Hangzhou. Seiko Technology received a reply letter on December 10th.It is reported that Blackstone Group may withdraw from its bid for Bausch & Lomb, an eye care company. People familiar with the matter said that Blackstone Group may withdraw from its joint bid for Bausch & Lomb. Earlier, it was reported that Blackstone and TPG (Detai Capital) jointly bid for Bausch & Lomb, an eye care company. At present, negotiations are still in progress. If Bausch & Lomb is willing to accept a lower price, or TPG finds another private equity investment group as a trading partner, the transaction may still be completed.The first day of listing, the new shares of Gem Boyuan opened sharply higher, and now it has risen by over 220%.

Li Pengxin, the former deputy secretary of the Party Committee of Xinjiang Uygur Autonomous Region, was prosecuted. It was learned from the Supreme People's Procuratorate today (11th) that the case of Li Pengxin, the former deputy secretary of the Party Committee of Xinjiang Uygur Autonomous Region, was investigated by the National Supervisory Commission (NSC), and was appointed by the Supreme People's Procuratorate to be examined and prosecuted by the People's Procuratorate of Baoji City, Shaanxi Province. Recently, the Baoji Municipal People's Procuratorate has filed a public prosecution with the Baoji Intermediate People's Court. (CCTV News)The aquaculture sector oscillated to raise Huaying Agriculture's daily limit, the aquaculture sector oscillated to raise, Huaying Agriculture's daily limit, Tianyu Bio and Chuangye International's previous daily limit, and Zhongshui Fishery, Minhe Shares and Xiaoming Shares followed suit.How to "bargain" the price difference of Chinese patent medicines? According to CCTV news, the National Medical Insurance Bureau responded that the price of proprietary Chinese medicines is affected by many factors, including the price of medicinal materials, production technology and brand value, in view of the large price difference of proprietary Chinese medicines and the problem of "bargaining". Centralized purchasing effectively squeezes the inflated price of drugs and improves the efficiency of capital use through market-oriented bidding and price-volume linkage. At the same time, the medical insurance bureau will strengthen monitoring and supervision to ensure the quality and supply of drugs and protect the rights and interests of patients.